ADVERTISEMENT
LIVE-DESK·Globale Marktredaktion·Last updated 14s ago
ADVERTISEMENT
Märkte/DevisenArticle

Novartis faces Phase 3 trial clinical setback for its $12B Avidity acquisition drug in myotonic dystrophy type 1

Finance Review Daily is tracking this developing story; finance review daily will provide updates as verified details become available.

SL
Sophie Laurent · FX & Rates Desk · 15 Sept 2026 · 04:20 · 1 Min. Lesezeit
Teilen
Novartis faces Phase 3 trial clinical setback for its $12B Avidity acquisition drug in myotonic dystrophy type 1

Novartis faces Phase 3 trial clinical setback for its $12B Avidity acquisition drug in myotonic dystrophy type 1.

Euro / US Dollar

EURUSD
Full profile →
1.1537▼ 0.12%
As of 14/09/2026, 21:00:00

Finance Review Daily is tracking this development following a report from the original source. Further verified details were not immediately available.

Dieser Artikel wurde mit KI-Unterstützung erstellt und von einer Finances-Review-Redakteurin bearbeitet.
ADVERTISEMENT
Artikel teilen
SL
Geschrieben von
Sophie Laurent
FX & Rates Desk

Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.

Mehr von Sophie Laurent →
ADVERTISEMENT
ADVERTISEMENT